Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Total Debt (2018 - 2022)

Lipocine (LPCN) has disclosed Total Debt for 5 consecutive years, with $1.5 million as the latest value for Q1 2022.

  • For the quarter ending Q1 2022, Total Debt fell 68.96% year-over-year to $1.5 million, compared with a TTM value of $1.5 million through Mar 2022, down 68.96%, and an annual FY2021 reading of $2.3 million, down 58.66% over the prior year.
  • Total Debt was $1.5 million for Q1 2022 at Lipocine, down from $2.3 million in the prior quarter.
  • Across five years, Total Debt topped out at $10.3 million in Q4 2018 and bottomed at $1.5 million in Q1 2022.
  • Average Total Debt over 5 years is $6.7 million, with a median of $6.4 million recorded in 2020.
  • The sharpest move saw Total Debt decreased 5.68% in 2019, then tumbled 68.96% in 2022.
  • Year by year, Total Debt stood at $10.3 million in 2018, then crashed by 30.33% to $7.1 million in 2019, then fell by 21.79% to $5.6 million in 2020, then plummeted by 58.66% to $2.3 million in 2021, then plummeted by 35.86% to $1.5 million in 2022.
  • Business Quant data shows Total Debt for LPCN at $1.5 million in Q1 2022, $2.3 million in Q4 2021, and $3.1 million in Q3 2021.